Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Orbactiv

- PMLiVE

Moving times

Continuity and stability are vital when it comes to the EMA's relocation when it leaves London

- PMLiVE

EMA sets aside £32m for temporary staff to help with Brexit move

As agency warns current tender system needs to be updated

EU flag

Europe’s cancer drug regulation is ‘broken’, claims study

Suggests EMA oncology approvals could lead to wasted funds and patient harm

Can Cinderella save us?

Motif Bio preps US filing after antibiotic clears phase III

The UK biopharma hopes to launch iclaprim by early 2019

- PMLiVE

EMA faces ‘permanent damage’ if forced to go to an unpopular city

Warns eight candidate cities wouldn't retain minimum staff numbers it needs

- PMLiVE

Takeda can’t sway NICE on oral myeloma therapy Ninlaro

Drug not recommended for NHS use in England and Wales

UK Life Sciences Strategy - one year on

EMA starts firming up its stance on personalised medicines

But draft guidelines won't be ready much before 2019

- PMLiVE

How to keep your name development on schedule after the recent EMA NRG announcement

Three key action points

- PMLiVE

Most of the EU would like to host the EMA

Nineteen member states will compete to host the agency when it leaves the UK

- PMLiVE

CHMP backs three immuno-oncology drugs for solid tumours

Roche, MSD and Merck/Pfizer are all on course for new European approvals later this year

- PMLiVE

Sanofi and Regeneron win CHMP nod for Dupixent

Atopic dermatitis treatment backed for European approval

- PMLiVE

Shake-up at GSK could claim antibiotics unit and UK facilities

The firm says its plans, which are expected to lead to 320 job cuts, are not related to Brexit

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links